|
Ocrelizumab is a humanized anti-CD20 monoclonal antibody, hence a CD20 antagonist. It targets mature B lymphocytes〔 (''Note: information included in this article only found in table present in print version of article.'')〕 and hence is an immunosuppressive drug candidate. It is under development for multiple sclerosis by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec. ==Clinical trials== It had reached Phase III clinical trials for rheumatoid arthritis and lupus erythematosus, and Phase II for multiple sclerosis (MS) and hematological cancer. In March 2010, Roche announced the suspension of clinical trials in rheumatoid arthritis and lupus erythematosus. This step followed excess deaths due to opportunistic infections. Development for multiple sclerosis continues.〔Katie Reid (2010-03-08). ''(Update 2. Roche suspends arthritis treatment after deaths. )'' Reuters. Retrieved 2010-03-08.〕 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Ocrelizumab」の詳細全文を読む スポンサード リンク
|